Free Trial
NYSEMKT:PHGE

BiomX (PHGE) Stock Price, News & Analysis

BiomX logo
$0.51 -0.07 (-12.09%)
(As of 11/20/2024 ET)

About BiomX Stock (NYSEMKT:PHGE)

Key Stats

Today's Range
$0.50
$0.58
50-Day Range
$0.51
$1.14
52-Week Range
N/A
Volume
103,796 shs
Average Volume
68,601 shs
Market Capitalization
$9.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.50
Consensus Rating
Buy

Company Overview

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
49th Percentile Overall Score

PHGE MarketRank™: 

BiomX scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BiomX has received no research coverage in the past 90 days.

  • Read more about BiomX's stock forecast and price target.
  • Earnings Growth

    Earnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BiomX is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BiomX is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BiomX has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for PHGE.
  • Dividend Yield

    BiomX does not currently pay a dividend.

  • Dividend Growth

    BiomX does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PHGE.
  • News Sentiment

    BiomX has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for BiomX this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for PHGE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BiomX insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.01% of the stock of BiomX is held by insiders.

  • Percentage Held by Institutions

    40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BiomX's insider trading history.
Receive PHGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter.

PHGE Stock News Headlines

Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
BiomX Announces a Mandatory Unit Separation
See More Headlines

PHGE Stock Analysis - Frequently Asked Questions

BiomX's stock was trading at $2.80 at the start of the year. Since then, PHGE shares have decreased by 81.8% and is now trading at $0.5090.
View the best growth stocks for 2024 here
.

BiomX Inc. (NYSEMKT:PHGE) released its earnings results on Monday, May, 15th. The company reported ($2.00) earnings per share for the quarter, missing analysts' consensus estimates of ($1.80) by $0.20.

BiomX shares reverse split on the morning of Monday, August 26th 2024. The 1-10 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

BiomX's top institutional shareholders include Ikarian Capital LLC (4.99%), Johnson & Johnson (1.07%), 8VC GP I LLC (0.61%) and Barclays PLC (0.14%). Insiders that own company stock include Israel Biofund Gp Limi Orbimed, Chidozie Ugwumba and Assaf Oron.
View institutional ownership trends
.

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), NVIDIA (NVDA), Zomedica (ZOM), Insulet (PODD) and Ford Motor (F).

Company Calendar

Last Earnings
5/15/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEMKT:PHGE
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.50
High Stock Price Target
$25.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+4,337.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.70 per share

Miscellaneous

Free Float
44,044,000
Market Cap
$9.22 million
Optionable
Not Optionable
Beta
1.31
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSEMKT:PHGE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners